Previous close | 7.50 |
Open | 7.50 |
Bid | 8.10 |
Ask | 8.80 |
Strike | 30.00 |
Expiry date | 2024-12-20 |
Day's range | 7.50 - 7.50 |
Contract range | N/A |
Volume | |
Open interest | 10 |
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
DUBLIN, May 28, 2024--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.